Biotech Values

[DewDiligence]

Romark Reports Phase-2 HCV Data for Nitazoxanide

[Nitazoxanide made a big splash at AASLD back in 2007 (#msg-24218770), but little has been heard about it since. I don’t see what all the fuss was about.

This PR is about the phase-2 trial in genotype-1 patients using a BID formulation; Romark reported data from a separate phase-2 in genotype-4 patients using a qD formulation in 2009 (#msg-35738696).]

http://finance.yahoo.com/news/Romark-Announces-Final-Data-prnews-3567810685.html?x=0&.v=1

›Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C

Study Presented at Late-Breaking Forum of the American Gastroenterological Association Institute during Digestive Disease Week 2010 Shows Higher SVR Rate for Patients Receiving Nitazoxanide plus Standard Therapy

Tuesday May 4, 2010, 3:45 pm EDT

TAMPA, Fla., May 4 /PRNewswire/ -- Romark Laboratories announced results from its STEALTH C-3 clinical trial, a phase 2 clinical study of nitazoxanide in treatment-naive patients with genotype 1 chronic hepatitis C. Study results were presented this afternoon as an oral communication at a late breaking forum of the American Gastroenterological Association Institute (AGA Institute) during Digestive Disease Week 2010 in New Orleans, Louisiana.

The study was a randomized, double-blind, placebo controlled trial conducted at thirteen centers in the United States in patients with genotype 1 chronic hepatitis C, 35% of whom had advanced stage 3 or 4 fibrosis. One-hundred and twelve patients were randomized to receive either nitazoxanide (500 mg twice daily) plus peginterferon alfa-2a (Pegasys®, F. Hoffman LaRoche) and ribavirin (Copegus®, F. Hoffman LaRoche) (n=75) or placebo plus Pegasys® and Copegus® (n=37). The primary endpoint of the study was sustained virologic response (SVR, undetectable HCV RNA 24 weeks after the end of treatment).

SVR occurred in 44% of patients treated with nitazoxanide plus standard therapy for 48 weeks versus 32% of patients treated with placebo plus standard therapy. [A 44% SVR rate after 48 weeks is nothing to write home about.] SVR rates were consistently higher in subsets of patients with high baseline viral load (41% vs. 29%) and in African Americans (38% vs. 20%). Safety analyses showed the rate of serious adverse events were similar for the nitazoxanide and placebo treatment groups. The only adverse events significantly associated with nitazoxanide were mild to moderate intermittent diarrhea and discolored urine.

Results of the STEALTH C-3 study are consistent with previously reported data from studies of nitazoxanide plus Pegasys® and Copegus® in treatment-naive patients with genotype 4 chronic hepatitis C.(1,2) The STEALTH C-3 study is the first trial of nitazoxanide in treatment-naive patients with genotype 1 chronic hepatitis C.

"We are pleased to achieve these results in a population representative of the broad range of hepatitis C patients in the United States, including 35% with advanced fibrosis," said Jean-Francois Rossignol, M.D., Ph.D., Chairman and Chief Science Officer of Romark and inventor of the drug. "We plan to initiate phase 3 clinical trials of nitazoxanide using our 675 mg controlled release tablets in combination with peginterferon with or without ribavirin later this year. The 675 mg controlled release tablets deliver a higher dose of nitazoxanide with a better pharmacokinetic profile. Additional clinical trials using the 675 mg controlled release tablets in genotype 1 and 4 patients are underway and include reduction of the duration of peginterferon to 24 weeks with and without ribavirin. We also plan to investigate combinations with direct acting antiviral drugs. Ultimately, we expect nitazoxanide to play an important role in a broad range of patients with chronic hepatitis C." [I doubt it.]

Nitazoxanide, the first of a new class of broad spectrum antiviral drugs called the thiazolides, is an investigational new drug for chronic hepatitis C. It is a potent inhibitor of hepatitis C virus (HCV) in replicon studies, and laboratory studies indicate that it does not induce viral mutations that confer drug resistance. Nitazoxanide is synergistic with interferon and direct acting antivirals in replicon studies. (4,6) In patients with chronic hepatitis C, the addition of nitazoxanide has not resulted in an increase in the toxicity associated with peginterferon and ribavirin. Studies in patients with genotype 4 chronic hepatitis C suggest that nitazoxanide may be used to replace ribavirin. The AIDS Clinical Trials Group (ACTG) in the United States is studying nitazoxanide plus peginterferon and ribavirin for treating chronic hepatitis C in patients coinfected with HIV.

"Patients with chronic hepatitis C are diverse in many respects with patient and virus characteristics that affect treatment outcomes (HCV genotype, viral load, stage of liver disease, IL28B genotype, race, body weight, coinfection with HIV or hepatitis B virus, and ability to tolerate treatment)," said Emmet B. Keeffe, Chief Medical Officer of Romark Laboratories. "The trend in therapy of chronic hepatitis C has been toward individualized therapy with combinations of antiviral drugs. There is a need for a new class of safe drugs with novel mechanism that can be used in combination with current standard therapy or with other new classes of drugs to improve treatment outcomes. We believe nitazoxanide can play an important role in these combinations."

…About Romark Laboratories

Romark Laboratories, L.C. (www.romark.com) is a biopharmaceutical company committed to the discovery and development of innovative new small molecules for treating infectious diseases and cancers.‹